Genmab to discontinue clinical development of acasunlimab

Genmab (GMAB) will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value-creating opportunities in its late-stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY, petosemtamab and rinatabart sesutecan, which are advancing in late-stage development. This decision is consistent with Genmab’s disciplined portfolio prioritization and capital allocation framework. “After careful consideration, we have decided to discontinue the acasunlimab program. Although the data have been encouraging, the compelling opportunities we see in our late-stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina-S, and we remain committed to executing these programs with speed and rigor,” said Jan van de Winkel, CEO. This decision does not impact Genmab’s full-year 2025 financial guidance.